Please ensure Javascript is enabled for purposes of website accessibility


Our Advisory Board

Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco

Advisory Board

Charles Nemeroff


Chair and professor with the Department of Psychiatry and Behavioral Sciences. Additionally, he directs the Institute for Early Life Adversity Research within the Department of Psychiatry and Behavioral Sciences as part of the Mulva Clinic for the Neurosciences.

His research is focused on the pathophysiology of mood and anxiety disorders with a focus on the role of child abuse and neglect as a major risk factor. He has also conducted research on the role of mood disorders as a risk factor for major medical disorders including heart disease, diabetes and cancer. He has published more than 1,100 research reports and reviews, and his research is currently supported by grants from the National Institutes of Health.

He has served as president of the American College of Psychiatrists and the American College of Neuropsychopharmacology, and he sits on the Scientific Advisory Board of the Brain and Behavioral Research Foundation. He is president-elect and a member of the board of directors of the Anxiety and Depression Association of America.

He has received a number of research and education awards, including the Kempf Award in Psychobiology, the Samuel Hibbs Award, the Research Mentoring Award, the Judson Marmor Award, the Vestermark Award and the Nasrallah Family Award for Advances in Psychiatric Neuroscience from the American Psychiatric Association; the Mood Disorders Award, the Bowis Award and the Dean Award from the American College of Psychiatrists; and the Julius Axelrod Award for mentoring from the American College of Neuropsychopharmacology. He was elected to the National Academy of Medicine in 2002. He was also named Alumnus of the Year from both the University of North Carolina and from the UNC School of Medicine. He received the doctorate honoris causa from Maimonides University in Buenos Aires in 2015.

Daniel R. Weinberger


Director and CEO of the Lieber Institute for Brain Development (LIBD) and a Professor of Psychiatry, Neurology, Neuroscience and Genetic Medicine at the Johns Hopkins University School of Medicine. He is regarded worldwide as one of the preeminent scientists in psychiatry research, having been at the forefront of scientific investigation of schizophrenia and related disorders for a generation. He attended college at the Johns Hopkins University, medical school at the University of Pennsylvania, and did residencies in psychiatry at Harvard Medical School and in neurology at George Washington University. He is board-certified in both psychiatry and neurology. Dr. Weinberger was instrumental in focusing the research landscape on the role of abnormal brain development as a risk factor for many psychiatric disorders. His lab identified the first specific genetic mechanism of risk for psychiatric illness, and the first genetic effects that account for variation in specific human cognitive functions and in human temperament. In addition, he and his colleagues developed the first high-fidelity animal model of schizophrenia. In 2003, Science magazine highlighted the genetic research of his lab as the second biggest scientific breakthrough of the year, second to the discovery of the origins of the cosmos. Dr. Weinberger is a member of the National Academy of Medicine of the National Academy of Sciences and the recipient of many honors and awards such as the K.J. Zulch Neuroscience Prize of the Max Planck Society in Germany, the NIH’s Directors Award, The William K. Warren Medical Research Institute Award, the Adolf Meyer Prize of the American Psychiatric Association, the Gold Medal Award of the Society of Biological Psychiatry, the Foundation’s Fund Prize from the American Psychiatric Association, and the Lieber Prize of the National Alliance for Research on Schizophrenia and Affective Disorders (now the Brain and Behavior Research Foundation). He has been president of major professional organizations.  He has published over 700 papers in high-profile, peer-reviewed journals and has authored or edited 11 books. He has also written extensively on the impact of mental illness in our society, health disparities in brain research and the role of the developing brain during adolescence.

Merit Cudkowicz


Dr. Cudkowicz is the Chief of Neurology at Massachusetts General Hospital, Director of the Sean M. Healey & AMG Center for ALS, and the Julieanne Dorn Professor of Neurology at Harvard Medical School. A member of the National Academy of Medicine, Dr. Cudkowicz has been a pioneer in promoting and devising more efficient methods for the development of new therapies for people with neurological disorders such as ALS and is one of the founders and co-directors of the Northeast ALS (NEALS) Consortium, a group of over 130 clinical sites in the United States and Canada dedicated to performing collaborative academic-led clinical trials in ALS.

Dr. Cudkowicz is also the Study Chair and Principal Investigator of the HEALEY ALS Platform Trial, a perpetual multi-center, multi-regimen clinical trial evaluating the safety and efficacy of investigational products for the treatment of ALS.

Dr. Cudkowicz received the American Academy of Neurology 2009 Sheila Essay ALS award, the 2017 Forbes Norris Award from the International MND Alliance, the 2017 Pinnacle Award from the Boston Chamber of Commerce and the 2019 Ray Adams American Neurological Association Award. She received a B.S. in Chemical Engineering from Massachusetts Institute of Technology, an M.D. from Harvard Medical School and a MSc. in Clinical Epidemiology from Harvard School of Public Health.